optimizing site selection

Select provides a data-driven approach to weighing selection and performance variables to aid in the identification of sites and target populations ideally suited to studies. Open sites on time and meet enrollment targets.

Let's Talk

meet enrollment targets

Competition for sites and enrollment issues has led to an increase in the number of non-active, non-enrolling (NANE) sites being activated for clinical trials.

Select reduces number of NANE sites:

  • Validates that sites have subjects
  • Integrates all data sources to create complete site profile
  • Profiles patient populations to design and tune protocols
  • Analyzes patient-to-site proximity and select most appropriate sites
11% of sites do not enroll a single subject, 37% under enroll. With actual enrollment timelines typically double planned timelines.
Ken Getz
Director of Sponsored Research Programs & Associate Professor
Ken Getz
Director of Sponsored Research Programs & Associate Professor

Nearly 60% of protocols require
one or more amendments, with 40%
of all amendments occurring before the
first study volunteer receives their first dose
in the clinical trial.

shorten cycle times

Increased protocol complexity — number of amendments, number of endpoints, eligibility criteria — has created challenges with site feasibility assessments.

Select reduces selection cycle time:

  • Integrated workflows to complete all site ID and selection activities
  • Reuses site profile and previous study data to pre-populate survey
  • Workflows to manage CDA, protocol amendments, site ID survey pre-study visits

facilitate global collaboration

Outsourcing of clinical trials has led to a reliance on global affiliates to understand all local processes and approvals, combined with ongoing study complexities, including volunteer to screen completion rate, has increased costs and delays.

Select reduces complexity:

  • Integrated workflows to complete all site ID and selection activities
  • Driving data-based business decisions and transparency
  • Providing site selection data for regulatory compliance
  • Mitigate recruitment and retention risks

20-50% of clinical trials will have
a “rescue mission” where new sites are
added in order to cure a shortfall in patient enrollments.

RELATED
RESOURCES

DATASHEET
WHITEPAPER
WHITEPAPER